Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial

Søren Snitker, Christina Egebjerg, Marie Frederiksen, Thomas Sparre, Søren Snitker, Christina Egebjerg, Marie Frederiksen, Thomas Sparre

No abstract available

Keywords: GLP-1 analogue; antiobesity drug; clinical trial; obesity therapy; phase III study; weight control.

Conflict of interest statement

All authors are employees of Novo Nordisk, Søborg, Denmark, and TS owns stock in the company.

Figures

FIGURE 1
FIGURE 1
Cumulative frequency of the two most frequent participant responses at week 68 for each item in the IDEA Part 1 (ease‐of‐use) questionnaire (A) and Part 2 (acceptability) questionnaire (B), reordered according to relatedness. Based on responses from 151 participants. IDEA, Injection Device Experience and Acceptability

References

    1. Food and Drug Administration . Wegovy – prescribing information. 2021. . Accessed March 11, 2022.
    1. European Medicines Agency . Wegovy – summary of product characteristics. 2022. . Accessed March 11, 2022.
    1. Wilding JPH, Batterham RL, Calanna S, et al. Once‐weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989‐1002.
    1. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double‐blind, double‐dummy, placebo‐controlled, phase 3 trial. Lancet. 2021;397(10278):971‐984.
    1. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403‐1413.
    1. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414‐1425.
    1. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138‐150.
    1. Klonoff DC, Bassock S, Dwyer A, et al. Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing. J Diabetes Investig. 2021;12(6):978‐987.
    1. Klonoff DC, Bassock S, Engels E, et al. Semaglutide single‐dose pen‐injector: post hoc analysis of summative usability testing for weight management. Diabetes Obes Metab. 2021;23(11):2590‐2594.
    1. Marchesini G, Pasqualetti P, Anichini R, et al. Patient preferences for treatment in type 2 diabetes: the Italian discrete‐choice experiment analysis. Acta Diabetol. 2019;56(3):289‐299.
    1. Snitker S, Andersen A, Lindskov PS, van Marle S, Sode BF, Sparre T. Comparison of the injection‐site experience of semaglutide in a single‐dose and a multidose pen‐injector. Diabetes Obes Metab. 2022;24(8):1643‐1646.
    1. Snitker S, Andersen A, Berg B, van Marle S, Sparre T. Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: a randomized, double‐blind trial in healthy subjects. Diabetes Obes Metab. 2021;23(6):1415‐1419.
    1. Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Mayo Clin Proc. 2016;91(9):1231‐1255.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe